Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

The FDA has approved GSK’s gepotidacin (Blujepa) for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older. The small-molecule drug is ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea. In the EAGLE-1 ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.

GSK plc, announced that the US FDA has approved Blujepa (gepotidacin) for the treatment of female adults (=40 kg) and paediatric patients (=12 years, =40 kg) with uncomplicated urinary tract ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...

Healthcare personnel (HCP) in Greece who were ill with COVID-19 and had at least one underlying medical condition missed more ...

The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...